Skip to main content
Journal cover image

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

Publication ,  Journal Article
McGrail, DJ; Pilié, PG; Rashid, NU; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, AB; Ueno, NT; Ferrarotto, R; Lin, S-Y ...
Published in: Ann Oncol
November 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

November 2022

Volume

33

Issue

11

Start / End Page

1204 / 1206

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Mutation
  • Lung Neoplasms
  • Immune Checkpoint Inhibitors
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • Biomarkers, Tumor
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., … Lin, S.-Y. (2022). Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol, 33(11), 1204–1206. https://doi.org/10.1016/j.annonc.2022.07.009
McGrail, D. J., P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, et al. “Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.Ann Oncol 33, no. 11 (November 2022): 1204–6. https://doi.org/10.1016/j.annonc.2022.07.009.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, et al. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022 Nov;33(11):1204–6.
McGrail, D. J., et al. “Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.Ann Oncol, vol. 33, no. 11, Nov. 2022, pp. 1204–06. Pubmed, doi:10.1016/j.annonc.2022.07.009.
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin S-Y. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol. 2022 Nov;33(11):1204–1206.
Journal cover image

Published In

Ann Oncol

DOI

EISSN

1569-8041

Publication Date

November 2022

Volume

33

Issue

11

Start / End Page

1204 / 1206

Location

England

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Mutation
  • Lung Neoplasms
  • Immune Checkpoint Inhibitors
  • Humans
  • Carcinoma, Non-Small-Cell Lung
  • Biomarkers, Tumor
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences